You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
興齊眼藥(300573.SZ):SQ-22031滴眼液治療神經營養性角膜炎Ⅱ期臨牀試驗首例受試者入組

格隆匯6月27日丨興齊眼藥(300573.SZ)公佈,公司研發的SQ-22031滴眼液於今日完成了“評估SQ-22031滴眼液治療神經營養性角膜炎(NK)患者的隨機、雙盲、安慰劑、平行對照Ⅱ期臨牀試驗”首例受試者入組,正式進入Ⅱ期臨牀試驗。

SQ-22031滴眼液是公司開發的用於治療NK的藥品,能促進感覺神經元和交感神經元生長和存活,並恢復受損神經元功能,可使患者的角膜損傷迅速癒合,角膜知覺和淚液生成量均得到改善。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account